Joshua Bhatt

Joshua Bhatt has conducted landmark studies on ctDNA-based minimal residual disease detection in colorectal cancer following curative-intent surgery. His research demonstrated that ctDNA positivity after resection predicts early recurrence with high accuracy, providing a blood-based window into residual disease that imaging cannot detect. He leads clinical trials evaluating ctDNA-guided adjuvant chemotherapy decisions, testing whether ctDNA-negative patients can safely avoid chemotherapy. His work is pioneering ctDNA as a clinical decision-making tool in curative colorectal cancer management.